Loss-of-function (LOF) mutations of EZH2 occur in several cancers including T-cell Acute Lymphoblastic Leukemia (T-ALL) and Acute Myeloid Leukemia (AML) (Ntziachristos et al., 2012; Zhang et al., 2012; Dohner et al., 2017; Liu et al., 2017). This evidence concerns the gene EZH2 and acute myeloid leukemia.